Until recently, the approach to the patient with metastatic melanoma was unchanged for nearly two decades. However, the field of melanoma research has experienced significant advances in the understanding of the biology of melanoma which has translated into the expansion of treatment options for patients with metastatic melanoma. With the advent of new medications for melanoma, many practitioners have not optimized the therapy for melanoma patients, mostly due to lack of familiarity with the new pharmaceuticals, including the proper indications, dosing, and sequence of medications. Furthermore, expert observations indicate that many patients are not provided with the full range of treatment options and appropriate sequence of therapy, personalized to them and the stage and biology of their tumors. Optimal and efficient melanoma management requires a multi-disciplinary approach involving dermatology, pathology, oncology, and surgery. Patients with early stage melanoma continue to have an excellent prognosis. Therefore, technology to aid in the early diagnosis of melanoma should be used by all clinicians.
This interdisciplinary, one-day conference will review advances in the molecular biology of melanoma and the use of newer targeted therapies, as well as examine how to incorporate the multidisciplinary care approach into patient care. Through didactic lectures, advances in the basic science of melanoma will be presented in the morning, and the afternoon will focus on new strategies, pharmaceuticals and technologies that are available and in development for the treatment of melanoma.